ScholarLens Back to search
2003•The Chinese Journal of Modern Applied PharmacyRequires access

Clinical study of irbesartan in the treatment of mild and moderate essential hypertension

Lin Yang

Open publisher page 0 citations

Abstract

OBJECTIVE To evaluate the clinical efficacy and safety of domestic irbesartan in the treatment of mild and moderate essential hypertension. METHOD A total of 57 patients with mild and moderate essential hypertension were enrolled in a randomized, double blind, control trial, irbesantan group 27 patients and valsartan group 30 patients. Patients were treated with 75～150mg·d -1 and 80～160mg·d -1 respectively, the dose regulation period was 2 weeks. RESULTS The blood pressure of patients in two groups decreased significantly after 4 weeks treatment. The total effective rates of irbesartan and valsartan group were 86.6% and 93.3% respectively, there was no significant difference between two groups.CONCLUSION Both domestic irbesartan and valsartan are effective and safe in the treatment of mild to moderate essential hypertension.

About this research paper

What this paper is about

OBJECTIVE To evaluate the clinical efficacy and safety of domestic irbesartan in the treatment of mild and moderate essential hypertension. METHOD A total of 57 patients with mild and moderate essential hypertension were enrolled in a randomized, double blind, control trial, irbesantan group 27 patients and valsartan group 30 patients. Patients were treated with 75～150mg·d -1 and 80～160mg·d -1 respectively, the dose regulation period was 2 weeks. RESULTS The blood pressure of patients in two groups decreased significantly after 4 weeks treatment. The total effective rates of irbesartan and valsartan group were 86.6% and 93.3% respectively, there was no significant difference between two groups.CONCLUSION Both domestic irbesartan and valsartan are effective and safe in the treatment of mild to moderate essential hypertension.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE To evaluate the clinical efficacy and safety of domestic irbesartan in the treatment of mild and moderate essential hypertension. METHOD A total of 57 patients with mild and moderate essential hypertension were enrolled in a randomized, double blind, control trial, irbesantan group 27 patients and valsartan group 30 patients. Patients were treated with 75～150mg·d -1 and 80～160mg·d -1 respectively, the dose regulation period was 2 weeks. RESULTS The blood pressure of patients in two groups decreased significantly after 4 weeks treatment. The total effective rates of irbesartan and valsartan group were 86.6% and 93.3% respectively, there was no significant difference between two groups.CONCLUSION Both domestic irbesartan and valsartan are effective and safe in the treatment of mild to moderate essential hypertension.

Key concepts: Irbesartan, Valsartan, Medicine, Essential hypertension, Blood pressure, Clinical trial, Urology, Clinical efficacy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical study of irbesartan in the treatment of mild and moderate essential hypertension — Research Paper | ScholarLens